Sanofi-aventis announced that it has signed an agreement to acquire Medley in Brazil. Medley is the third largest pharmaceutical company and the number one generic company in Brazil. In 2008 Medley's sales amounted to 458 million BRL (around 153 million euros), including two third of those sales in generics. With a generic portfolio of 127 products, Medley is very well positioned to benefit from the growth of the Brazilian generic market, which is expected to remain over 20 per cent per annum in the coming years.
The details can be read here.
No comments:
Post a Comment